Market capitalization | CAD73.91m |
Enterprise Value | CAD68.47m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | CAD0.00 |
EBIT (operating result TTM) EBIT | CAD-31.84m |
Free Cash Flow (TTM) Free Cash Flow | CAD-18.90m |
Cash position | CAD6.01m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
4 Analysts have issued a Sernova forecast:
4 Analysts have issued a Sernova forecast:
Oct '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.54 -0.54 |
20%
20%
|
|
EBITDA | -31 -31 |
23%
23%
|
EBIT (Operating Income) EBIT | -32 -32 |
23%
23%
|
Net Profit | -32 -32 |
17%
17%
|
In millions CAD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sernova Corp. is a clinical stage regenerative medicine company. It engages in the business of developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins and hormones missing within the body. The firm also focuses in the manufacture and clinical evaluation of the cell pouch for insulin-dependent diabetes. The company was founded on August 19, 1998 and is headquartered in London, Canada.
Head office | Canada |
CEO | Jonathan Rigby |
Employees | 17 |
Founded | 1998 |
Website | www.sernova.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.